Resources
  • All Resources
  • Articles
  • Blog Highlights
  • Case Studies
  • eBooks
  • Infographic
  • White Papers
  • Webinars
Webinar

Specialty Pharmacy Data Strategy: Contracting for the Right Data

How will you use analytics to measure commercial success and improve patient experience for your specialty brand? An effective specialty data contracting strategy starts at the finish line and works backward. The decisions you make in terms of data fields, sub-status granularity, reporting frequency, and contract language, determine the metric outputs that are possible. In this webinar, we take a closer look at how the right specialty data contracting decisions enable a richer set of analytics and insights.

View Webinar

Blog

Opioid Crisis Exposes Vulnerabilities in Suspicious Order Monitoring

The American opioid crisis exposed gaps in the reporting systems designed to flag suspicious orders of pharmaceutical products classified as controlled substances. Pharma manufacturers are now facing increased scrutiny and need a new approach to suspicious order monitoring. In this post, IntegriChain Solutions Principal Shivani Patel introduces an upgrade to the traditional methodology that uses Enriched 867 data to provide greater visibility across pharmacy locations and wholesale distributors in aggregate.

Read Blog Post

Webinar

How to Self Police Revenue Leakage due to 340B Program Non-Compliance

There is broad agreement across the pharmaceutical industry and Congress that that 340B program needs more oversight and statutory change. But with so much congressional paralysis and midterm elections on the horizon, it’s highly unlikely that changes will occur anytime soon. The status quo leaves manufacturers with few remedies for pursuing suspected diversion or duplicate rebate claims generated by providers or pharmacies. In this webinar, we’ll look at examples of non-compliance, specifically diversion and duplicate discounting, that manufacturers and Payers can flag and act on. Using IntegriChain’s analytics platform to crosswalk pharmacy sell-in data, rebates, and chargebacks, we’ll demonstrate how manufacturers can identify non-compliant 340 transactions.

View Webinar

Blog

3 Key Opportunities to Improve Specialty Patient Initiation

Prior Authorization (PA) is required for nearly all specialty products and is largely responsible for delayed patient initiation. Lengthy PA delays can ultimately result in cancellations for new patient referrals, adherence/persistence problems, and lower patient satisfaction. There are several ways specialty brands can improve patient initiation by implementing data-driven patient support strategies. Successful interventions to streamline patient initiation have the potential to speed Time to First Fill and increase overall Fill Rate for new patient referrals.

Read Blog Post

Blog

The Economics of Rare Disease and Implications for Payer Contract Strategy

Rare diseases affect 30 million people in the United States, which roughly equates to 10% of the population. In 2017, 40% of the novel drugs approved by the FDA were designated to treat a rare disease. As approvals for rare disease treatments increase, these products account for an ever increasing share of overall pharmaceutical sales. The Payer community’s is reaching for value as per patient costs rise. This post discusses value-based contracts as a mutually beneficial solution for Payers and pharmaceutical manufacturers and the meaningful role analytics can play in executing and managing these innovative agreements.

Read Blog Post

Infographic

Commercial Readiness Timeline

Based on our experience as the access operations team and data platform for more than 100 pharma companies that are launching novel drugs in the US, we've developed a Commercial Readiness Timeline guide--taking you from 12-months pre-launch for readiness to 12-months post-launch for commercialization--that you can save and reference as you prep for market. This timeline covers all the strategies and tasks you need to address for, Government Contracts & Pricing, Commercial Contracts & Rebates, Financial Planning & Analysis, Distribution, Primary Care Access, and Specialty Access.

View Infographic

Paper

Using Market Analogs for FP&A During Product Launch

Estimating the value of net sales adjustments from a Finance perspective can be very difficult due to a lack of available data and market information. The problem is especially acute before launch and in the first few quarters the product is on the market. IntegriChain often provides market-level benchmarks and analogs (i.e., metadata) that can serve as the foundation of a data-driven approach to financial planning & analysis for product launch. Manufacturers adopting this methodology would then have a credible source as the basis for estimating sales adjustments and a methodology that's been readily accepted by external audit firms.

Download Paper

Webinar

Formulary and Contract Compliance – Uncover Rebate Savings and Reduce Financial Risk

IntegriChain Market Access has been able to leverage subject matter expertise, tools, and techniques to identify between 1.25% and 2.5% of a payers' total rebate spend as non-compliant. In this webinar, our in-house experts John Still and Tina Cullen highlight how two critical compliance validations can yield rebate dollars and reduce financial risk for bio/pharma manufacturers working to provide patients access to products in competitive therapeutic classes.

View Webinar

Webinar

Best Practices in Specialty Data Services Contracts

The expansion of specialty networks to include more pharmacies, and the growing complexity within these networks, is forcing manufacturers to make trade offs as they contract for data critical to understanding and impacting the patient journey. In this webinar, we look at how the structure of data contracts with SPs and proactive analytics concepts that allow specialty brands to impact the patient journey.

View Webinar

Webinar

Contracting & Pricing Product Launch Strategies for Small- and Mid-Sized Pharma

The list of challenges associated with commercializing a product is long and diverse. Every decision seems to affect patient access to your product and has long-term implications on growth and profitability. Too often manufacturers make commercialization decisions, negotiate agreements, and set prices that aren't fully understood with the benefit of experience and solid analytics. In this webinar, IntegriChain Payer & Market Access Segment Leader David Carlson will draw on unique insights and best practices learned as part of dozens of successful small molecule retail and specialty product launches to analyze the most significant commercialization hurdles. Topics include: contracting, negotiating discounts, pricing, and measuring channel performance.

View Webinar

Webinar

Controlling Risks through Order Management: Addressing Price Transparency Laws and the Opioid Crisis

The need for the type of accountability provided by order management technology has never been greater. Price Transparency legislation passed in a handful of states in 2017, including California. Additional states are working on their own bills. These laws have the potential to encourage price speculation. At the same time, the opioid epidemic has grown into a full-scale public health crisis and has placed the pharmaceutical industry under the microscope.  In this webinar, we'll demonstrate how effective order management can limit a manufacturer's susceptibility to price speculation and serve as a safeguard against suspicious orders of highly-regulated, controlled drugs. 

View Webinar

Webinar

Reducing Revenue Leakage with Chargeback Analytics

Automated chargeback applications execute many important validations such as contract eligibility, membership verification, and price checks. Nonetheless the most obvious sources of revenue leakage, sales and return unit quantities, are not checked at all.  One example of potential loss occurs when a trade partner receives a return of salable product but does not send a chargeback reversal. This webinar examines a hands-on approach to identifying and prioritizing missing or incorrect chargeback claims. 

View Webinar

Webinar

Using Analytics to Identify High Value, Under Indexed Retail Pharmacies

Multiple factors are challenging patients as they seek access to innovative brands at the retail pharmacy. Complicated payer/plan policy restrictions, including prior authorizations, often delay initiation of therapy. Escalating out-of-pocket costs are another obstacle patients must navigate. This webinar highlights how IntegriChain Retail Analytics uses geographic, payer/plan, and brand/market data to identify high value, under indexed pharmacies.

View Webinar

Case Study

Optimize Rebate Investments with PBMs & HMOs

A manufacturer had historically based Managed Care pricing decisions on highly subjective information and emotion rather than historical data on customer and contract performance. Limited and inaccurate data led to impromptu “how are we doing?” check-in calls. As a result, members of the Pricing Committee realized that this environment was leading to substantial inefficiencies and marginal rebate investments with its managed care customers. PharmaMetrics was brought in to help integrate managed care data and optimize rebate investments.

Read Case Study

Case Study

Improving Managed Care ROI

A disconnect existed between the contract negotiation business function and the contract analyst business function. The belief was that contract performance was not meeting expectations set at the outset of the agreement. PharmaMetrics applied a Rational Pricing methodology to help the manufacturer determine if its investment was optimized.

Read Case Study

Article

Use Data Analytics to Monitor 340B Discount Drug Pricing

As the industry refocuses on more innovative, expensive specialty drugs and channel designs shift, however, manufacturers are growing increasingly concerned with the 340B Drug Discount Program. Analytics will help manufacturers in their quest to discern how and where products are discounted.

Read Article

Paper

The Value of the 1%

Manufacturers know that ensuring product availability is very difficult, especially when product distribution is so expensive. Further complicating matters, sales do not equal demand, leading to a real commerce optimization problem within the demand network.

Download Paper

eBook

Leaving the Legacy

Pharmaceutical manufacturers continue to struggle with ensuring product availability, controlling distribution cost, and increasing forecast accuracy. This is often because they are using outdated or constrained legacy platforms. In this ebook, learn how three of our customers moved away from disparate systems to IntegriChain’s informed applications.

Download eBook

eBook

Mobile-Optimized Channel Management and Demand Sensing Analytics

The latest release of the IntegriChain channel management cloud offers mobile user access and near real-time demand sensing to maximize the accessibility and value of channel data through the life sciences supplier enterprise.

Download eBook

Webinar

Using Channel Data Analytics for 340B Monitoring and Audit Support

IntegriChain Director of Solution Engineering Dave Weiss and guest speaker Michael Townsend, IDC Health Insights Research Manager, Life Sciences Business Systems Strategies explore the changing breadth of the 340B Discount Drug Program and the insights offered in the Health Resources and Services Administration’s (HRSA’s) recently released mega-guidance, including results of its program-integrity audits.  

View Webinar

Webinar

Introducing IntegriChain Scorecard Analytics

IntegriChain Executive Director of Product Management Sunay Shah explores a major enhancement to IntegriChain Scorecard, unlocking the power of Scorecard data with robust data analysis and visualization capabilities. This enhancement allows Scorecard users to utilize their robust Scorecard data to further maximize pay-for-performance by analyzing channel investment against performance through IntegriChain’s powerful query and reporting tools. 

View Webinar

Webinar

Introducing the IntegriChain Summer Release

Sunay Shah, Executive Director of Product Management, introduces you to the  IntegriChain Summer Release. This release expands IntegriChain’s custom visualization and analytics suite for life sciences channel data and analytics. Learn how this new release for Demand Visibility and Builder delivers collaborative actionable insight discovery and intuitive business intelligence of the downstream channel for life sciences manufacturers.

View Webinar

Webinar

Outside-In Order Management

IntegriChain and Lora Cecere, Founder & CEO of Supply Chain Insights, take a deep dive into the new “outside-in” methodology of using actual channel data to make informed order decisions. Lora focuses on how suppliers can use advanced analytics to sense order flows and yield exceptions to drive a better supply chain response.

View Webinar

Webinar

The Impact of Downstream Inventory on Gross-to-Net Accounting

In this webinar, we explore best practices for estimating inventory when calculating gross-to-net to eliminate gross overstatements or understatements of pipeline liabilities that do not triangulate well with other commercial commerce datasets. Attendees will learn about best practices for using auditor-approved downstream inventory data and analytics for preparing for loss of exclusivity (LOE), tightening gross-to-net reserves, and improving visibility to gross sales forecast risk.

View Webinar

Webinar

IntegriChain Builder Intelligence Tool

Builder radically improves the actionability of channel analytics, driving down the cost of total ownership of wholesaler and specialty data sources while maximizing the value of manufacturer investments in data agreements. This webinar covers merging disparate data sources into one report or visualization, manipulating extracted data using custom calculations, and more.

View Webinar

Article

Finding the Value in Outsourced Contract Administration

The growing complexity of managed markets contract support makes outsourcing a near-necessity for emerging pharmaceutical companies, and a better option for big pharma.

Read Article

eBook

The Value of 1%

Manufacturers know that ensuring product availability is very difficult, especially when product distribution is so expensive. Further complicating matters, sales do not equal demand, leading to a real commerce optimization problem within the demand network. Download The Value of 1% White Paper to explore how you can optimize demand network commerce with informed applications.

Download eBook

eBook

Daily Business Management Trade & Channel

In today’s era of Pay-for-Performance agreements and lean channel inventory, pharmaceutical manufacturers want to know how to better align product availability with the overall cost of distribution. The answer can be found in a new approach to trade data utilization called Daily Business Management. Download the Daily Business Management ebook to learn about the next evolution in channel agreements.

Download eBook

Blog

Leveraging Distributor Contract Management to Optimize Evolving DSAs

As distribution service agreements evolve over time, manufacturers must have the ability to run what-if analyses on actual scorecard data to analyze the overall effect various changes under consideration would have on trade partner payments. In this post, we look at how Distributor Contract Management can be leveraged to optimize changes to DSAs.

Read Blog Post

Blog

Specialty Pharmacy Status/Sub-Status Analysis Highlights Inconsistencies in Data Quality

IntegriChain examined the quality and granularity of status/sub-status data across 40 specialty pharmacies representing different classes of trade (small independent, mid-sized payer, large PBM, etc.). The records we combed through included 15 specialty brands in five therapeutic categories: Immunology, Hematology, Virology, Oncology, and Pulmonary/Respiratory.

Read Blog Post

Webinar

Unlock the Power of Scorecard Analytics to Maximize Pay-for-Performance

This webinar covers major enhancements to trade partner scorecard functionality found within IntegriChain Distribution Analytics. These enhancements allow Scorecard users to utilize robust trade partner agreement data to further maximize pay-for-performance by analyzing channel investment against performance through IntegriChain's powerful Data on Demand and reporting tools.

View Webinar

Article

How Not to Handle Rebates

As financial pressures increase, pharmaceutical companies are paying greater attention to cutting costs and increasing efficiency. However, rebate expenditures continue to expand.

Read Article

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71